A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid Tumours
This phase I trial studies the side effects and best dose of ziv-aflibercept when given
together with pembrolizumab in treating patients with solid tumours that have spread to other
places in the body. Ziv-afibercept works by decreasing blood and nutrient supply to the
tumour, which may result in shrinking the tumour. Monoclonal antibodies, such as
pembrolizumab, may block tumour growth in different ways by targeting certain cells. Giving
ziv-aflibercept together with pembrolizumab may be a better treatment for patients with
advanced solid tumours.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society